Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305703 | PMC |
| http://dx.doi.org/10.1053/j.gastro.2020.06.044 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study.
J Clin Lipidol
August 2024
CPC Clinical Research and Division of Cardiology, University of Colorado School of Medicine, Aurora, CO (Dr Szarek); State University of New York, Downstate Health Sciences University, Brooklyn, NY (Dr Szarek).
Article Synopsis
- - The ODYSSEY OUTCOMES trial evaluated the impact of alirocumab, a drug that targets cholesterol, compared to a placebo on major cardiovascular events in patients with recent acute coronary syndrome, involving over 18,000 participants.
- - Results showed that while both men and women experienced significant reductions in cholesterol levels and cardiovascular events with alirocumab, women had higher initial cholesterol and lipoprotein(a) levels and more co-morbidities.
- - The study concluded that alirocumab improves cardiovascular outcomes post-acute coronary syndrome for both sexes, especially in individuals with higher baseline levels of lipoprotein(a).
The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?
Gastroenterology
April 2021
Gastroenterology Unit, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy.
Adherence of Infusible Biologics During the Time of COVID-19 Among Patients With Inflammatory Bowel Disease: A Nationwide Veterans Affairs Cohort Study.
Gastroenterology
October 2020
Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center of Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.
PLoS One
October 2019
Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada.
Background: Compliance to disease modifying therapy (DMT) is associated with a reduced risk of relapse, lower healthcare resource utilization, and improved health-related quality of life in patients with multiple sclerosis (MS). Our objective was to assess the compliance and discontinuation rates of fingolimod relative to other oral, injectable, and infusible DMTs available on the market at the time of the study in Canada in patients with relapsing-remitting MS (RRMS).
Methods And Findings: We conducted a retrospective claims analysis.
Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents.
J Clin Oncol
February 2018
Jalpa A. Doshi, Pengxiang Li, Hairong Huo, and Amy R. Pettit, University of Pennsylvania, Philadelphia, PA; and Katrina A. Armstrong, Massachusetts General Hospital, Boston, MA.
Purpose The number of novel oral anticancer agents is increasing, but financial barriers may limit access. We examined associations between out-of-pocket (OOP) costs and reduced and/or delayed treatment initiation. Methods This retrospective claims-based study used 2014 to 2015 data from a large, proprietary, integrated database and included Medicare and commercial insurance enrollees with a new, adjudicated prescription for any of 38 oral anticancer agents.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!